.png)
We analyse life sciences assets from preclinical to commercial stages. We propose our services to investors and biotech companies.
ABOUT OUR RESEARCH
Our research interprets the science beneath the assets in its financial context.
Our trusted partners
.png){kind=logo}
Download
Reviewing basic sciences, we anticipated the successfull translation from preclinical to phase I of the lead drug of the company, capturing a 50% upside in the stock price for a HNWI client.
PRECLINICAL TO CLINICAL PHASE
CLINICAL TO COMMERCIAL STAGE
While 9 Wall Street analysts out of 10 were predicting a FDA approval, we anticipated their Complete Response Letter after reviewing their clinical data. This allowed an institutional client to earn a 30% profit on the news release.
VALUATION AT COMMERCIAL STAGE
Sanofi is facing a patent clift. We built a quantitative model to predict the revenue of Dupixent until 2030 to valuate the stock price and anticipate its trajectory.
ELAM1 is a Switzerland-registered equity research firm specializing in healthcare and biotechnology. With more than 15 years of experience in healthcare finance, we assist financial professionals and life sciences companies to invest in the healthcare and biotechnology sectors.
ABOUT ELAM1
Assets Under Advisement
.png)
$500M+
Clients: USA, UAE, Switzerland, France
Global
Years Of Experience In Life Science Finance
15+
OUR SERVICES
We propose tailored services across all stages of life sciences business. From venture investors willing to value early preclinical data to assessing the M&A perspectives for a biotech firm, we adapt our research to our client needs.
.png)
Contact us to get a tailored offer.
Life science valuations is not only financial. It is scientific.
CASE STUDIES
.png)
.png)
Investment research
for individual investors.
We analyse life sciences assets from preclinical to commercial stages. We propose our services to investors and biotech companies.
ABOUT OUR RESEARCH
Our research interprets the science beneath the assets in its financial context.
.png)
ELAM1 is a Switzerland-registered equity research firm specializing in healthcare and biotechnology. With more than 15 years of experience in healthcare finance, we assist financial professionals to invest in the healthcare and biotechnology sectors.
.png)
15+
Years Of Experience in Life Science Finance
Global
Clients: USA, UAE, Switzerland, France
$500M+
Assets Under Advisement
Our Trusted Partners
Contact us to get a tailored offer
ABOUT ELAM1
Preclinical to clinical phase
Reviewing fundamental researches, we anticipated the successfull translation from preclinical to phase I of the lead drug of the company, capturing a 50% upside in the stock price for a HNWI client.
While 9 Wall Street analysts out of 10 were predicting a FDA approval, we anticipated their Complete Response Letter after reviewing their clinical data. This allowed an institutional client to earn a 30% profit on the news release.
Clinical to commercial stage
Valuation at commercial stage
.png){kind=logo}
Sanofi is facing a patent clift. We built a quantitative model to predict the revenue of Dupixent until 2030 to valuate the stock price and anticipate its trajectory.
Download
We propose tailored services across all stages of life sciences business. From venture investors willing to value early preclinical data to assessing M&A perspectives for a biotech firm, we adapt our research to our client's needs.
OUR SERVICES
Life science valuation is not only financial. It is scientific.
CASE STUDIES